Market Overview

UPDATE: Morgan Stanley Reiterates on AbbVie After Competitor's Schizophrenia Drug Fails

Share:
Related
Eli Lilly's Taltz Gets Approval For Label Expansion in US
A Lazarus Act For This Pharma ETF
How Much Trading Volume Is Enough In Swing Trades? (Investor's Business Daily)

In a report published Tuesday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on AbbVie (NYSE: ABBV), but removed the $57.00 price target.

In the report, Morgan Stanley noted, “Targacept's (not covered) cognitive deficits in schizophrenia (CDS) drug, TC-5619, failed. This drug is similar to ABBV's ABT-126, which is being tested in Ph. IIb in both cognition in Alzheimer's and CDS. We have been estimating 20% odds of ABBV success in one of the two indications.”

AbbVie closed on Monday at $53.37.

Latest Ratings for ABBV

DateFirmActionFromTo
Nov 2017BMO CapitalMaintainsMarket Perform
Oct 2017Leerink SwannMaintainsOutperform
Oct 2017BarclaysMaintainsEqual-Weight

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABBV)

View Comments and Join the Discussion!

Partner Center